Mycophenolic acid

Catalog No.S2487 Synonyms: Mycophenolate, RS-61443

For research use only.

Mycophenolic acid (Mycophenolate, RS-61443) is a potent IMPDH inhibitor and the active metabolite of an immunosuppressive drug, used to prevent rejection in organ transplantation.

Mycophenolic acid Chemical Structure

CAS No. 24280-93-1

Selleck's Mycophenolic acid has been cited by 8 Publications

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Other Antineoplastic and Immunosuppressive Antibiotics Products

Biological Activity

Description Mycophenolic acid (Mycophenolate, RS-61443) is a potent IMPDH inhibitor and the active metabolite of an immunosuppressive drug, used to prevent rejection in organ transplantation.
In vitro

Mycophenolic acid inhibits inosine-5'-monophosphate dehydrogenase (IMPDH) by acting as a replacement for the nicotinamide portion of the nicotinamide adenine dinucleotide cofactor and a catalytic water molecule. [1] Mycophenolic acid (MPA), an inhibitor of inosine monophosphate dehydrogenase, in nanomolar concentrations blocks proliferative responses of cultured human, mouse and rat T lymphocytes and B lymphocytes to mitogens or in mixed lymphocyte reactions. Mycophenolic acid (MPA) suppresses mixed lymphocyte reactions when added 3 days after their initiation. Mycophenolic acid also inhibits antibody formation by polyclonally activated human B lymphocytes. Mycophenolic acid is an immunosuppressive agent reversibly inhibiting proliferation of T and B lymphocytes and antibody formation, with a profile of activity different from that of other immunosuppressive drugs. [2] Mycophenolic acid inhibits the formation of antibodies to sheep erythrocytes. Mycophenolic acid also suppresses, in a dose-related manner, the generation of cytotoxic T-lymphocytes against allogeneic cells in mice and prevents the elimination of allogeneic cells. [3] Mycophenolic acid induces apoptosis and cell death in a large proportion of activated CD4+ T cells. [4]

In vivo Mycophenolic acid has lymphocyte-selective anti-proliferative effects in mice and can inhibit both cell-mediated and humoral immune responses without major side effects. [3]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 320.34


CAS No. 24280-93-1
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1=C2COC(=O)C2=C(C(=C1OC)CC=C(C)CCC(=O)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05005221 Recruiting Behavioral: Automated text messages Kidney Transplant University of Michigan July 11 2022 Not Applicable
NCT04473924 Withdrawn Drug: Mycophenolate Mofetil Infection|Transplant;FailureKidney University of California San Francisco July 2022 Phase 2
NCT05120570 Recruiting Drug: VIC- 1911 Acute Leukemia|Myelodysplastic Syndromes|Myeloproliferative Neoplasm|Lymphoma Masonic Cancer Center University of Minnesota March 17 2022 Phase 1|Phase 2
NCT05202145 Completed Drug: ALXN2050|Drug: Cyclosporine|Drug: Tacrolimus|Drug: MMF Healthy Alexion Pharmaceuticals January 11 2022 Phase 1

(data from, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Mycophenolic acid | Mycophenolic acid supplier | purchase Mycophenolic acid | Mycophenolic acid cost | Mycophenolic acid manufacturer | order Mycophenolic acid | Mycophenolic acid distributor